montyman

Regenerative Medicine: Big Pharma's Next Frontier

What a shame that Aastrom Biosciences is declining badly despite having a promising and safe product (autologous), and yet Osiris is doing well despite the fact that Chondrogen FAILED in the trials (no surprise since it was designed to maximize profit margins without regard to whether the approach actually worked). Oh well.